Premium
Prevalence and risk of metabolic syndrome in patients with systemic lupus erythematosus: A meta‐analysis
Author(s) -
Sun Chong,
Qin Wen,
Zhang YuHui,
Wu Yan,
Li Qian,
Liu Mei,
He ChunDi
Publication year - 2017
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.13153
Subject(s) - medicine , meta analysis , cochrane library , odds ratio , confidence interval , metabolic syndrome , medline , publication bias , population , obesity , environmental health , political science , law
Purpose To conduct a systematic review and meta‐analysis assessing the prevalence of metabolic syndrome (MetS) in patients with systemic lupus erythematosus ( SLE ) and the association between SLE and MetS. Method A database search of PubMed, the Cochrane Library, EMBASE , China National Knowledge Infrastructure ( CNKI ), Weipu database and Wanfang database updated until March 2017 was conducted. The pooled prevalence, the odds ratio ( OR ) and 95% confidence intervals ( CI ) were calculated. Publication bias was assessed with Egger's test method. Results In the study of the prevalence of MetS in patients with SLE , 47 studies containing 8367 subjects were included. These studies were published from 2006 to 2016. The pooled prevalence of MetS in patients with SLE was 0.26 (95% CI : 0.23–0.29). In the study of the relationship between SLE and MetS, 24 studies involving 2744 cases and 3028 controls were included. Comparing to control, the SLE patients had high risk of MetS ( OR = 1.88, 95% CI : 1.54–2.30, P = 0.000). Conclusion The systematic review and meta‐analysis demonstrated the prevalence of MetS in patients with SLE was 26% and the patients with SLE were more prone to having MetS than the control population. The analysis was a basic summary of all relevant researches and provided valuable evidence for prevention and treatment.